Subscribe
Sign in
Home
Notes
Archive
Leaderboard
About
Latest
Top
The Gut Punch Weekly #24
GLP-1s elevate eye disease risk, Lilly and Camurus partner on long-acting obesity drugs, GLP-1s linked to unexpected pregnancies, and more!
Jun 11
1
Share this post
The Gut Punch
The Gut Punch Weekly #24
Copy link
Facebook
Email
Notes
More
The Gut Punch Weekly #23
Production missteps ended Novo Nordisk's dominance, Regeneron secures $2B deal for Hansoh's obesity drug, Regeneron drug combo preserves muscle mass…
Jun 4
1
Share this post
The Gut Punch
The Gut Punch Weekly #23
Copy link
Facebook
Email
Notes
More
May 2025
The Gut Punch Weekly #22
MAHA report calls for broad food & health shakeup, Doctors See Broad Medical Uses for GLP-1s, Wegovy Offers Limited $199 Deal, and more!
May 28
Share this post
The Gut Punch
The Gut Punch Weekly #22
Copy link
Facebook
Email
Notes
More
The Gut Punch Weekly #21
Novo's CEO gets the boot, compounders exploit a loophole to keep selling GLP-1 knockoffs, a conversation with the founder of SuperGut, and more!
May 21
Share this post
The Gut Punch
The Gut Punch Weekly #21
Copy link
Facebook
Email
Notes
More
The Gut Punch Weekly #20
Trump targets high prices of GLP-1s, Zepbound outperforms Wegovy in weight loss, WeightWatchers files for bankruptcy, weight loss drugs alter taste for…
May 14
Share this post
The Gut Punch
The Gut Punch Weekly #20
Copy link
Facebook
Email
Notes
More
The Gut Punch Weekly #19
Wegovy shows promise in treating liver disease, Novo secures preferred spot on CVS formulary, WHO endorses weight-loss drugs, and more!
May 7
Share this post
The Gut Punch
The Gut Punch Weekly #19
Copy link
Facebook
Email
Notes
More
April 2025
The Gut Punch Weekly #18
Novo declares truce with telehealth cos, GLP-1 compounders keep losing in court, poultry intake linked to significantly higher early death risk, and…
Apr 30
Share this post
The Gut Punch
The Gut Punch Weekly #18
Copy link
Facebook
Email
Notes
More
The Gut Punch Weekly #17
There's only one story that really matters this week – Eli Lilly Surpasses Novo Nordisk as Lilly's daily oral pill matches Ozempic for weight loss.
Apr 23
Share this post
The Gut Punch
The Gut Punch Weekly #17
Copy link
Facebook
Email
Notes
More
The Gut Punch Weekly #16
Pfizer halts obesity drug due to safety concerns, Zepbound users maintain weight loss over three years, FDA seizes hundreds of counterfeit Ozempic…
Apr 16
Share this post
The Gut Punch
The Gut Punch Weekly #16
Copy link
Facebook
Email
Notes
More
The Gut Punch Weekly #15
Trump blocks Medicare coverage of weight loss drugs, Novo Nordisk invests $1.1B in Brazil production, Ozempic may help cut food costs and waste, and…
Apr 9
Share this post
The Gut Punch
The Gut Punch Weekly #15
Copy link
Facebook
Email
Notes
More
The Gut Punch Weekly #14
Americans are snacking less, Novo bets $1B on new drug, Rybelsus' cardiovascular impacts are mixed, Danone adapts marketing strategy for the GLP-1 era…
Apr 2
Share this post
The Gut Punch
The Gut Punch Weekly #14
Copy link
Facebook
Email
Notes
More
March 2025
The Gut Punch Weekly #13
Snack sales are on the decline, Wegovy prices now lower for cash buyers, Lilly beats Novo to Indian market, Novo spends $200M to license "triple…
Mar 26
Share this post
The Gut Punch
The Gut Punch Weekly #13
Copy link
Facebook
Email
Notes
More
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
